Kinase Modulator Scaffolds With BBB Penetration and Target Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for medical conditions caused by aberrant kinase activity, such as autoimmune diseases and neurodegenerative diseases, lack effective inhibitors or activators, leading to inadequate management of these disorders.
Innovation Solution
Development of compounds that modulate the activity of protein kinases like LRRK2, NUAK1, and TYK2, with improved pharmacological properties for therapeutic use and radio-labeled tracers for diagnostic imaging, allowing for targeted treatment and identification of kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no effective kinase inhibitors or activators are developed, then current treatments remain inadequate, but developing new compounds increases research and development complexity
Solution Approach 1:
The patent segments the kinase target into specific binding pockets and interaction regions, designing compounds that target distinct functional domains of LRRK2, NUAK1, and TYK2 kinases. This allows for selective inhibition or activation of specific kinase isoforms and reduces off-target effects, thereby improving treatment reliability while managing development complexity through focused molecular design
Solution Approach 2:
The patent employs systematic parameter changes in compound structure-activity relationships, optimizing molecular properties such as lipophilicity, molecular weight, and functional group composition to achieve desired pharmacological profiles. This approach enables fine-tuning of kinase modulator efficacy and selectivity, improving treatment effectiveness while providing a methodical framework that manages R&D complexity
2Ease of operation
If compounds are designed to penetrate the blood-brain barrier, then central nervous system target accessibility improves, but molecular structure constraints increase
Solution Approach 1:
The patent systematically adjusts molecular parameters including reducing molecular weight below 500 Da, optimizing logP values for appropriate lipophilicity, and minimizing hydrogen bond donors to facilitate blood-brain barrier penetration. These parameter optimizations enable CNS target accessibility while establishing clear structural guidelines that actually reduce overall design complexity
Solution Approach 2:
The patent incorporates multiple structural features within single compounds, including aromatic rings for pi-stacking interactions, flexible alkyl chains for membrane permeability, and specific functional groups for kinase binding. This composite molecular design achieves blood-brain barrier penetration while the modular approach allows systematic assembly that manages structural complexity
3Reliability
If high affinity binding to kinase targets is achieved, then therapeutic efficacy improves, but selectivity and specificity requirements increase
Solution Approach 1:
The patent designs compounds with specific local interactions at the kinase binding site, including hydrogen bonds with catalytic residues, hydrophobic interactions in subpockets, and electrostatic interactions with the ATP-binding cleft. This localized optimization achieves high affinity binding while the specificity for particular amino acid residues in the kinase active site ensures selectivity, managing the complexity through focused molecular recognition design
Solution Approach 2:
The patent employs water molecules and ionic interactions as intermediaries between the compound and kinase target, mediating high-affinity binding through coordinated hydrogen bonding networks. These intermediary interactions enhance binding affinity while providing a degree of flexibility that accommodates variations in kinase structure, thereby improving therapeutic efficacy while managing selectivity requirements
4Measurement precision
If radio-labeled tracers are developed for PET imaging, then diagnostic capability improves, but compound synthesis and handling complexity increases
Solution Approach 1:
The patent separates the diagnostic function from the therapeutic compound by developing radio-labeled tracers that are structurally related but distinct from the kinase inhibitors. This segmentation allows the tracer to be optimized for imaging properties (radioisotope attachment, pharmacokinetics) while the parent compound is optimized for therapeutic efficacy, improving diagnostic capability while managing synthesis complexity through modular radiolabeling approaches
Solution Approach 2:
The patent creates simplified copies or analogs of the therapeutic compound that are specifically designed for PET imaging. These tracer copies maintain the core pharmacophore for kinase binding but incorporate radioisotopes and structural modifications that enhance imaging properties. The copying approach allows systematic development of tracers using established radiolabeling methodologies, improving diagnostic precision while providing a framework that manages synthesis complexity
Data Source
AI summary
The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for treating diseases, such as autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, Alzheimer's disease, Parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 40 to 146; examples 1 to 63; compounds 1 to 248; tables 1 to 3). Preferred compounds are e.g. 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds. An exemplary compound is e.g. 5-(2,6-difluorophenyl)-8-methoxy-1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine (example 49). (Formula (II):